ESSA Pharma Inc. (EPIX)

NASDAQ: EPIX · IEX Real-Time Price · USD
2.98
-0.08 (-2.61%)
Mar 28, 2023, 4:30 PM EDT - Market closed
-2.61%
Market Cap 131.40M
Revenue (ttm) n/a
Net Income (ttm) -32.75M
Shares Out 44.09M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,054
Open 3.10
Previous Close 3.06
Day's Range 2.96 - 3.10
52-Week Range 1.40 - 8.03
Beta 2.11
Analysts Buy
Price Target 22.03 (+639.26%)
Earnings Date May 9, 2023

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Can... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 50
Stock Exchange NASDAQ
Ticker Symbol EPIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for EPIX stock is "Buy." The 12-month stock price forecast is $22.03, which is an increase of 639.26% from the latest price.

Price Target
$22.03
(639.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

2 weeks ago - PRNewsWire

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

1 month ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022

Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC pati...

1 month ago - PRNewsWire

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

1 month ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA , Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

3 months ago - PRNewsWire

ESSA Pharma to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

4 months ago - PRNewsWire

J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment

Shares of Essa Pharma Inc. EPIX, +1.38% fell 28.6% in premarket trading on Monday after the company said Johnson & Johnson JNJ, +1.49% suspended enrollment in a Phase 1 clinical trial for Essa's exper...

Other symbols: JNJ
5 months ago - Market Watch

ESSA Provides an Update on its Clinical Collaboration with Janssen

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

Other symbols: JNJ
5 months ago - PRNewsWire

ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

5 months ago - PRNewsWire

Why Is ESSA Pharma (EPIX) Stock Up 156% Today?

ESSA Pharma (NASDAQ: EPIX) stock is flying higher on Wednesday following the release of data from a Phase 1/2 study of EPI-7386. EPI-7386 is a drug in development for the treatment of metastatic cast...

5 months ago - InvestorPlace

Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions obse...

5 months ago - PRNewsWire

ESSA Pharma Appoints Philip Kantoff to its Board of Directors

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on dev...

7 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

8 months ago - PRNewsWire

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals Conference Call and Webcast Today at 5...

9 months ago - PRNewsWire

ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

10 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developin...

11 months ago - PRNewsWire

ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on dev...

1 year ago - PRNewsWire

ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders inhib...

1 year ago - PRNewsWire

ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

1 year ago - PRNewsWire

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, California  and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on devel...

1 year ago - PRNewsWire

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANIT en bAsed Chimera (ANITAC™) degraders degrade full length, mutant and splice variant forms of A...

1 year ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021

HOUSTON, Texas and VANCOUVER, Canada, Feb. 3, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...

1 year ago - PRNewsWire

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

1 year ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021

VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel thera...

1 year ago - PRNewsWire

ESSA Pharma to Participate in Three Upcoming Investor Conferences

VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...

1 year ago - PRNewsWire